BioLASCO Taiwan Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
November 03, 2022 at 03:32 pm EDT
Share
BioLASCO Taiwan Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 59.75 million compared to TWD 59.81 million a year ago. Net income was TWD 11.81 million compared to TWD 14.07 million a year ago. Basic earnings per share from continuing operations was TWD 0.46 compared to TWD 0.55 a year ago. Diluted earnings per share from continuing operations was TWD 0.46 compared to TWD 0.55 a year ago.
For the nine months, sales was TWD 166.56 million compared to TWD 169.01 million a year ago. Net income was TWD 29.76 million compared to TWD 31.8 million a year ago. Basic earnings per share from continuing operations was TWD 1.16 compared to TWD 1.24 a year ago. Diluted earnings per share from continuing operations was TWD 1.16 compared to TWD 1.24 a year ago.
BioLASCO Taiwan Co., Ltd. is a Taiwan-based company mainly engaged in the production of Specific Pathogen Free (SPF) laboratory animals and the high-value special-mode experimental animals, as well as the introduction and production of highly-applicable disease-mode animals. The company also provides equipment related to feeding, supplies and testing platform, life science research and pharmaceutical development services.